These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24888607)

  • 1. Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.
    Kim TJ; Park CK; Yeo CD; Park K; Rhee CK; Kim J; Kim SJ; Lee SH; Lee KY; Yoon HK
    J Surg Oncol; 2014 Sep; 110(3):245-51. PubMed ID: 24888607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
    Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
    Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.
    Zhang NN; Liu YT; Ma L; Wang L; Hao XZ; Yuan Z; Lin DM; Li D; Zhou YJ; Lin H; Han XH; Sun Y; Shi Y
    PLoS One; 2014; 9(1):e84501. PubMed ID: 24404167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.
    Vanderlaan PA; Yamaguchi N; Folch E; Boucher DH; Kent MS; Gangadharan SP; Majid A; Goldstein MA; Huberman MS; Kocher ON; Costa DB
    Lung Cancer; 2014 Apr; 84(1):39-44. PubMed ID: 24513263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
    Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
    Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.
    Dang AH; Tran VU; Tran TT; Thi Pham HA; Le DT; Nguyen L; Nguyen NV; Thi Nguyen TH; Nguyen CV; Le HT; Thi Nguyen ML; Le VT; Nguyen PH; Vo BT; Thi Dao HT; Nguyen LT; Van Nguyen TC; Bui QN; Nguyen LH; Nguyen NH; Thi Nguyen QT; Le TX; Do TT; Dinh KT; Do HN; Phan MD; Nguyen HN; Tran LS; Giang H
    Sci Rep; 2020 Feb; 10(1):2707. PubMed ID: 32066856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
    Chaft JE; Dagogo-Jack I; Santini FC; Eng J; Yeap BY; Izar B; Chin E; Jones DR; Kris MG; Shaw AT; Gainor JF
    Lung Cancer; 2018 Aug; 122():67-71. PubMed ID: 30032847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.
    Gaughan EM; Cryer SK; Yeap BY; Jackman DM; Costa DB
    Lung Cancer; 2013 Mar; 79(3):193-7. PubMed ID: 23273562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of genomic changes on treatment of lung cancer.
    Cardarella S; Johnson BE
    Am J Respir Crit Care Med; 2013 Oct; 188(7):770-5. PubMed ID: 23841470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.
    Liu Q; Huang Q; Yu Z; Wu H
    Clin Respir J; 2022 Mar; 16(3):216-225. PubMed ID: 35081265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.
    Rangachari D; Yamaguchi N; VanderLaan PA; Folch E; Mahadevan A; Floyd SR; Uhlmann EJ; Wong ET; Dahlberg SE; Huberman MS; Costa DB
    Lung Cancer; 2015 Apr; 88(1):108-11. PubMed ID: 25682925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
    Ishida M; Iwasaku M; Doi T; Ishikawa T; Tachibana Y; Sawada R; Ogura Y; Kawachi H; Katayama Y; Nishioka N; Morimoto K; Tokuda S; Yamada T; Takayama K
    Cancer Sci; 2024 May; 115(5):1656-1664. PubMed ID: 38450844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth.
    Kobayashi Y; Mitsudomi T; Sakao Y; Yatabe Y
    Ann Oncol; 2015 Jan; 26(1):156-161. PubMed ID: 25361983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
    Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG
    Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing.
    Wang Y; Tian PW; Wang WY; Wang K; Zhang Z; Chen BJ; He YQ; Li L; Liu H; Chuai S; Li WM
    Oncotarget; 2016 Oct; 7(40):65208-65217. PubMed ID: 27564104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.
    Zhao F; Xu M; Lei H; Zhou Z; Wang L; Li P; Zhao J; Hu P
    PLoS One; 2015; 10(2):e0117333. PubMed ID: 25706305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.
    Tembuyser L; Tack V; Zwaenepoel K; Pauwels P; Miller K; Bubendorf L; Kerr K; Schuuring E; Thunnissen E; Dequeker EM
    PLoS One; 2014; 9(11):e112159. PubMed ID: 25386659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
    Bodor JN; Bauman JR; Handorf EA; Ross EA; Clapper ML; Treat J
    J Cancer Res Clin Oncol; 2023 May; 149(5):1755-1763. PubMed ID: 35708776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized targeted therapy for lung cancer.
    Wu K; House L; Liu W; Cho WCS
    Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of genetic mutations in non-small cell lung cancer in Morocco.
    Morjani O; Benkirane N; Errihani H; Elfahime EM; Lakhiari H
    Pan Afr Med J; 2024; 47():116. PubMed ID: 38828424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.